Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.
The monoclonal antibody Rituximab is useful for treatment of patients with B-cell non-Hodgkin's lymphoma. We phenotypically analyzed reconstitution of peripheral B cells in a male patient with follicular lymphoma following their depletion with Rituximab. CD19+ and CD20+ B cell counts in peripheral blood decreased rapidly following Rituximab treatment. Six months after the end of treatment, a few CD19+ B cells were detected in peripheral blood. These cells had a naive B cell phenotype (IgD+, CD27-) and they expressed high levels of CD38 and CD24, which show that the B cell pool was repopulated mainly with immature, naive B cells.
Abulayha
Abdulmunem M
AM
Cell Biology Research Group, Biotechnology Research Center, Twisha, Tripoli, Libya. abdulmunem09@hotmail.com
Tabal
Salah A
SA
Shawesh
Eman I
EI
Elbasir
Mohamed A
MA
Elbanani
Abdulrhman S
AS
Lamami
Yosra M
YM
Bredan
Amin
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016175:B-Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects*; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects*; D002452:Cell Count; D002469:Cell Separation; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D008224:Lymphoma, Follicular / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab